The stock of Vertex Pharmaceuticals, Inc. (VRTX) has seen a 1.70% increase in the past week, with a -0.93% drop in the past month, and a 3.12% flourish in the past quarter. The volatility ratio for the week is 1.28%, and the volatility levels for the past 30 days are at 1.79% for VRTX. The simple moving average for the last 20 days is -0.70% for VRTX’s stock, with a simple moving average of 10.71% for the last 200 days.
Is It Worth Investing in Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Right Now?
The price-to-earnings ratio for Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) is 29.93x, which is above its average ratio. Moreover, the 36-month beta value for VRTX is 0.35. Analysts have varying opinions on the stock, with 12 analysts rating it as a “buy,” 10 as “overweight,” 5 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for VRTX is 257.54M and currently, short sellers hold a 1.57% of that float. On March 22, 2024, VRTX’s average trading volume was 1.30M shares.
VRTX) stock’s latest price update
The stock of Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) has increased by 0.87 when compared to last closing price of 412.11.Despite this, the company has seen a gain of 1.70% in its stock price over the last five trading days. Seeking Alpha reported 2024-03-21 that Vertex Pharmaceuticals has a dominant Cystic fibrosis franchise and plans to launch five new products by 2028, including a next-generation CF drug and a non-opioid pain management drug. VRTX stock has stalled in 2024 due to lower revenue growth projections for the year, which is unappealing for growth investors. The long-term potential of its drug pipeline may justify buying for long-term growth investors.
Analysts’ Opinion of VRTX
Many brokerage firms have already submitted their reports for VRTX stocks, with Wolfe Research repeating the rating for VRTX by listing it as a “Outperform.” The predicted price for VRTX in the upcoming period, according to Wolfe Research is $515 based on the research report published on February 15, 2024 of the current year 2024.
Evercore ISI, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $438, previously predicting the price at $436. The rating they have provided for VRTX stocks is “In-line” according to the report published on February 06th, 2024.
VRTX Trading at -2.01% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.29% of loss for the given period.
Volatility was left at 1.79%, however, over the last 30 days, the volatility rate increased by 1.28%, as shares sank -2.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.26% lower at present.
During the last 5 trading sessions, VRTX rose by +1.70%, which changed the moving average for the period of 200-days by +24.31% in comparison to the 20-day moving average, which settled at $418.07. In addition, Vertex Pharmaceuticals, Inc. saw 2.17% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from Arbuckle Stuart A, who sale 5,034 shares at the price of $425.70 back on Feb 26 ’24. After this action, Arbuckle Stuart A now owns 49,691 shares of Vertex Pharmaceuticals, Inc., valued at $2,142,974 using the latest closing price.
ALTSHULER DAVID, the EVP, Global Research and CSO of Vertex Pharmaceuticals, Inc., sale 4,239 shares at $425.70 during a trade that took place back on Feb 26 ’24, which means that ALTSHULER DAVID is holding 25,813 shares at $1,804,542 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- 0.39 for the present operating margin
- 0.87 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc. stands at 0.37. The total capital return value is set at 0.2. Equity return is now at value 22.99, with 17.56 for asset returns.
Based on Vertex Pharmaceuticals, Inc. (VRTX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at 4.38. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is 86.22.
Currently, EBITDA for the company is 3.93 billion with net debt to EBITDA at -2.0. When we switch over and look at the enterprise to sales, we see a ratio of 9.91. The receivables turnover for the company is 6.31for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.99.
Conclusion
To wrap up, the performance of Vertex Pharmaceuticals, Inc. (VRTX) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
